Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of paricalcitol vs maxacalcitol in hemodialysis patients with secondary hyperparathyroidism
jRCT2080220874Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paricalcitol and maxacalcitol in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Abbott Laboratories.
02
Drugs
paricalcitolmaxacalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080220874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220874.